The changing landscape of cancer vaccines: developing in situ vaccination

Abigail Pinchbeck, Assistant Editor, BioInsights, speaks to Joshua Brody, Director, Lymphoma Immunotherapy Program, Tisch Cancer Institute, Mount Sinai

Dr Joshua Brody runs the Lymphoma Program at Mount Sinai. He received his BA in Biochemistry from Harvard, MD from SUNY Stony Brook, completed an internal medicine residency at Yale-New Haven Hospital, and postdoctoral fellowships at Stanford in the labs of Ed Engleman, Jonathan Pollack, and Ron Levy. He came to Mount Sinai in 2011 to develop a translational cancer immunotherapy lab and build the Lymphoma Program. The lab has been highly productive, translating novel therapies from mouse models into early phase clinical trials and publishing in high impact journals, such as Nature Medicine, Nature Communications, Journal of Clinical Oncology, Blood, and Cancer Discovery. The lab has been fortunate to receive funding from the NIH, the Damon Runyon Cancer Research Foundation, the Cancer Research Institute, the Lymphoma Research Foundation, the Follicular Lymphoma Foundation and several industry collaborators.

Cancer vaccines could prove a valuable addition to the immunotherapy repertoire, but they are yet to reach their full potential. To bring these medicines to patients, several developmental hurdles must be overcome. In this interview, Joshua Brody, Director of the Lymphoma Immunotherapy Program at Tisch Cancer Institute discusses his work on in situ vaccination, and how personalized cancer vaccines could become the next immunotherapy frontier in 2023, and beyond.

Please enter your email to access content Read now